Company news

TherapeuticsMD, Inc. news in 2021

TherapeuticsMD, Inc.'s news releases, calls and decks from 2021, newest first.

View company

U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

December 9, 2021

TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

December 7, 2021

TherapeuticsMD Announces Third Quarter 2021 Financial Results

November 10, 2021

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer

November 10, 2021

TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021

October 26, 2021

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

October 14, 2021

Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month

September 1, 2021

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

August 22, 2021

TherapeuticsMD Announces Appointment of Hugh O’Dowd as President

August 8, 2021

TherapeuticsMD Announces Second Quarter 2021 Financial Results

August 3, 2021

TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021

July 25, 2021

TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

May 24, 2021

The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award

May 23, 2021

TherapeuticsMD Announces First Quarter 2021 Financial Results

May 5, 2021

TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting

May 2, 2021

TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021

April 28, 2021

TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium

April 7, 2021

TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results

March 1, 2021

TherapeuticsMD Announces Participation in Upcoming Investor Conferences

February 28, 2021

TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021

February 22, 2021

TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock

February 15, 2021

TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock

February 10, 2021

TherapeuticsMD Announces Underwritten Public Offering of its Common Stock

February 9, 2021

Calls in 2021

Decks in 2021